Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated...
Saved in:
| Main Authors: | Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2797 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
by: Sohil Reddy, et al.
Published: (2025-07-01) -
Enlarged piloid astrocytoma of the midbrain: recurrence or pseudoprogression? A clinical case
by: Yu. Yu. Trunin, et al.
Published: (2016-03-01) -
Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
by: M.S. Ruban, et al.
Published: (2025-03-01) -
BIOLOGICAL RESPONSE OF TREATMENT WITH SAFFRON PETAL EXTRACT ON CYTOKYNE-INDUCED OXIDATIVE STRESS AND INFLAMMATION IN THE CACO-2/THP1 COCOLTURE MODEL
Published: (2025-08-01) -
Search for long-lived charged particles using large specific ionisation loss and time of flight in 140 fb −1 of pp collisions at s $$ \sqrt{s} $$ = 13 TeV with the ATLAS detector
by: The ATLAS collaboration, et al.
Published: (2025-07-01)